JRoon71, ??? I never said anything about secret trials. I said that AMRN may keep secret their drug development of any new version of an EPA drug. Denner is a "science guy" as he has an undergraduate degree from MIT & an advanced degree & doctorate from Yale. You seem to intentionally miss my point which is simply that Alex Denner may want to interest BP in AMRN not only on the basis of Vascepa but also for the prospects of whatever AMRN may have in drug development. Not that AMRN would be conducting any new trials for any new drug, but certainly explain to BP what the potential of any new drug (or delivery system for EPA) could be for a BP.